AIM Vaccine Co., Ltd (HKG: 6660), based in China, has received clinical trial approval from the National Medical Products Administration (NMPA) for its mRNA vaccine targeting respiratory syncytial virus (RSV).
RSV is a leading cause of mortality in infants under one year old and significantly contributes to respiratory infections and fatalities among the elderly. The virus can lead to repeat infections, affecting individuals of all ages. Currently, there are no approved antiviral drugs for RSV available for clinical use worldwide.- Flcube.com
